Supply Chain

After a year filled with immense scrutiny over high drug prices, drug companies still made annual price hikes on many medications, although the increases were smaller than previous years, according to Reuters.

Allergan will eliminate more than 1,000 positions in anticipation of generic competition surrounding its popular dry-eye drug Restasis, reports Bloomberg.

Spark Therapeutics' Luxturna, the first gene therapy to gain FDA approval for the treatment of a rare, inherited retinal disease that can lead to blindness, will cost patients $850,000 for a one-time treatment, or $425,000 per eye, CNBC reports.

The FDA issued a Class I recall Jan. 2 for a heart device manufactured and distributed by a unit of Johnson & Johnson — citing a faulty valve, according to Reuters.

The average price hike for 20 of the nation's top-selling brand-name prescription drugs has  decreased for the fifth consecutive year, according to an analysis completed by STAT.

A delay on the ACA's medical device tax expired Jan. 1, putting the 2.3 percent levy into effect, according to a Reuters report.

San Diego-based Dignity Health's efforts to reduce plastic straw use across the system's 39 hospitals most captured readers' attention in December.

The FDA on Dec. 28 permitted the marketing of Sanuwave's Dermapace System to treat adults with diabetic foot ulcers.

The usage, sterilization practices and inherent design of a flexible scope limit the device's life to three years, per AHA guidelines. The life cycle costs of flexible ureteroscopes can be even more challenging, especially in a procedure that offers historically…

The FDA approved 46 new drugs in 2017, a more than two-fold increase from the year prior, according to Reuters.